DK

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Retrieved on: 
Thursday, August 18, 2022
Exercise, DK, Patient, Boehringer Ingelheim, Company, Nasdaq Copenhagen, NASDAQ, DKK, Nasdaq, AstraZeneca, Fine chemical, Security (finance), Association, Zealand Pharma

The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs.

Key Points: 
  • The increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs.
  • Employee warrant programs are part of Zealand Pharmas incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a pre specified price, the exercise price, in specific predefined time periods before expiration.
  • The amendments to Zealand Pharmas Articles of Association entailed by the share capital increase have been set out below.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Greene Concepts Sponsors Dawson Cram for Upcoming NASCAR 2022 Xfinity Series Races

Retrieved on: 
Wednesday, August 17, 2022
U.S. Securities and Exchange Commission, Drink, CEO, GLOBE, Chevrolet, Security (finance), Camping, NASCAR Camping World Truck Series, Kansas Speedway, Securities Act of 1933, Blue Ridge Mountains, Securities Exchange Act of 1934, OTC Markets Group, Health, Disclosure, Relaxation, BE, Partnership, Water, NASCAR, Cram Racing Enterprises, Silverado, Mineral, NBC Sports, 2018 NASCAR Camping World Truck Series, NASCAR Xfinity Series, Fed, Awareness, Xfinity, NBC, DK, Camping World, Safe harbor, September 3, 2020 NASCAR Xfinity Series, Courage, Company, Darlington Raceway, Online gambling, Bottled water, Sport

The BE WATERTM brand will have a prominent spotlight on DKs racecar in multiple Xfinity Series races during the 2022 season.

Key Points: 
  • The BE WATERTM brand will have a prominent spotlight on DKs racecar in multiple Xfinity Series races during the 2022 season.
  • See the Xfinity Series Schedule webpage to view additional 2022 Xfinity Series racing information to include viewing platforms.
  • We are thrilled to have Greene Concepts BE WATER artesian spring bottled water brand along with its Happy Mellow brand on our racecars during the upcoming 2022 Xfinity Series notes DK Cram.
  • Lenny Greene, CEO of Greene Concepts states, We are delighted to sponsor Dawson and his team for the 2022 NASCAR Xfinity Series racing circuit.

Zealand Pharma Announces Financial Results for the First Half of 2022

Retrieved on: 
Thursday, August 11, 2022
FDA, Q&A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intellectual property, ADSS, NDA, DK, Obesity, Type 2 diabetes, ADS, Failure, Private Securities Litigation Reform Act, Half-life, Growth, Sale, American depositary receipt, Research, Lists of diseases, SBS, Patient, COVID-19, Boehringer Ingelheim, Education, Financial result, Structured Product Labeling, Program, Nasdaq Copenhagen, Peptide, Short bowel syndrome, Asset purchase agreement, MannKind Corporation, PIN, Congenital hyperinsulinism, Intention, DKK, Nasdaq, Professional corporation, Diabetes, Webcast, AstraZeneca, Advertising, Weight loss, Food, Efficiency, Zealand Pharma, Fine chemical, Pharmaceutical industry, Cryptocurrency, Renewable energy, CHI

Copenhagen, DK and Boston, MA, U.S. August 11, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Key Points: 
  • Copenhagen, DK and Boston, MA, U.S. August 11, 2022 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
  • 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced financial results for the first half of 2022 and provided a corporate update.
  • Cash, cash equivalents, and marketable securities: DKK 864.4 million / USD 120.7 million as of June 30, 2022 (June 30, 2021: DKK 1,282.9 million / USD 205.0 million).
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Updated notice to holders of ADSs regarding termination of Deposit Agreement

Retrieved on: 
Monday, August 8, 2022
DTC, BNY Mellon, Bank, ADSS, DK, Sale, Ownership, American depositary receipt, Eastern Time Zone, OTCM QX ADR 30 Index, Patient, Company, Boehringer Ingelheim, Deposit, BIC, Nasdaq, AstraZeneca, Eastern, ADR, Zealand Pharma, Security (finance), Life insurance

20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and development of innovative peptide-based medicines, hereby provides notice to holders of American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs) representing deposited ordinary shares of the Company regarding termination of the Deposit Agreement (the Deposit Agreement), dated August 8, 2017, among the Company, The Bank of New York Mellon, as depositary (the the Depositary), and Owners and ADR Holders (ADR Holders).

Key Points: 
  • 20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and development of innovative peptide-based medicines, hereby provides notice to holders of American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs) representing deposited ordinary shares of the Company regarding termination of the Deposit Agreement (the Deposit Agreement), dated August 8, 2017, among the Company, The Bank of New York Mellon, as depositary (the the Depositary), and Owners and ADR Holders (ADR Holders).
  • On August 3, 2022, ADR Holders were notified by the Depositary that the Depositary will terminate the Deposit Agreement effective at 5:00 PM (Eastern Time) on November 2, 2022.
  • Under the terms of the Deposit Agreement, ADR Holders have until at least November 7, 2022, to surrender their Zealand ADRs for delivery of the underlying shares.
  • Subsequent to November 7, 2022, under the terms of the Deposit Agreement, the Depositary may attempt to sell the underlying shares.

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the U.S.-Based Nasdaq Global Select Market

Retrieved on: 
Monday, August 8, 2022
U.S. Securities and Exchange Commission, Disclosure, ADSS, DK, ADS, Securities Exchange Act of 1934, SEC, American depositary receipt, Security (finance), Compliance, Patient, Boehringer Ingelheim, Company, Therapy, Nasdaq Copenhagen, Intention, Â, DKK, Nasdaq, Private Securities Litigation Reform Act, AstraZeneca, Solution, Efficiency, Fine chemical, USD, Zealand Pharma

The companys ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares.

Key Points: 
  • The companys ordinary shares will continue to be listed on Nasdaq Copenhagen, which is the primary source of liquidity and trading flexibility for Zealand shares.
  • Zealand has been listed on the Nasdaq Copenhagen since November 2010 under the ticker ZEAL.CO and trades in DKK.
  • The company subsequently listed its ADSs on the Nasdaq Global Select Market in the U.S. in August 2017 under the ticker ZEAL and trades in USD.
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.

Zealand Pharma Hosts Conference Call on August 11 at 4 pm CET (10am ET) to Present Second Quarter Results for 2022

Retrieved on: 
Thursday, August 4, 2022
Boehringer Ingelheim, Q&A, CET, Nasdaq, AstraZeneca, DK, PIN, Patient, Senior, Zealand Pharma, Investor, Pharmaceutical industry

20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2022.

Key Points: 
  • 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 11, 2022 at 4 pm CET (10 am ET) following the announcement of results for the second quarter of 2022.
  • Telephone dial-in information and a unique personal access PIN will be provided upon registration via the following link, https://register.vevent.com/register/BI0687000737bf4bdda7d667f72d07be30 .
  • Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines.
  • All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

Delek US Holdings Reinstates Regular Quarterly Dividend at $0.20 per share

Retrieved on: 
Monday, August 1, 2022
Dorado, Time, Environment, U.S. Securities and Exchange Commission, Forward-looking statement, NYSE, Partnership, Board, DK, Multimedia, Share repurchase, Company, Board of directors, Delek, Petroleum

BRENTWOOD, Tenn., Aug. 1, 2022 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) (the "Company" or "Delek US") announced that its Board of Directors reinstated the Company's regular quarterly cash dividend on its common stock of $0.20 per share payable to all shareholders of record of the Company's common stock as of the close of business on August 22, 2022. The payment date for the dividend will be September 6, 2022. 

Key Points: 
  • Avigal Soreq, President and Chief Executive Officer of Delek US, stated, "Returning cash to shareholders is a key priority for our Company and reinstating a regular dividend lays a foundation that we believe can be supported through various business cycles.
  • Separately, the expanded share repurchase authorization reflects our desire to deliver increased cash returns during periods of strong free cash flow generation.
  • Delek US Holdings, Inc. is a diversified downstream energy company with assets in petroleum refining, logistics, asphalt, renewable fuels and convenience store retailing.
  • Delek US and its affiliates also own the general partner and an approximate 80 percent limited partner interest in Delek Logistics.

Delek Logistics Partners, LP to Host Second Quarter 2022 Conference Call on August 4th

Retrieved on: 
Wednesday, July 6, 2022
Permian, Recycling, Review, Acquisition, Transport, Gulf Coast of the United States, Marketing, DKL, Partnership, DK, NYSE, Delaware Basin, Twitter, Delek, Multimedia, Public relations, Petroleum, Delek US, LP

BRENTWOOD, Tenn., July 6, 2022 /PRNewswire/ -- Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing second quarter 2022 results before the U.S. stock market opens on Thursday, August 4, 2022.

Key Points: 
  • BRENTWOOD, Tenn., July 6, 2022 /PRNewswire/ -- Delek Logistics Partners, LP (NYSE: DKL) ("Delek Logistics") today announced that the Partnership intends to issue a press release summarizing second quarter 2022 results before the U.S. stock market opens on Thursday, August 4, 2022.
  • Investors may also wish to listen to Delek US Holdings, Inc.'s (NYSE: DK) ("Delek US") second quarter 2022 earnings conference call on Thursday, August 4, 2022 at 10:00 a.m. CT (11:00 a.m.
  • Market trends and information disclosed by Delek US may be relevant to Delek Logistics, as it is a consolidated subsidiary of Delek US.
  • Delek US Holdings, Inc. (NYSE: DK) ("Delek US") owns the general partner interest as well as a majority limited partner interest in Delek Logistics Partners, LP, and is also a significant customer.

Delek US Holdings to Host Second Quarter 2022 Conference Call on August 4th

Retrieved on: 
Wednesday, July 6, 2022
Dorado, Gulf Oil LP, DK, Partnership, Company, Multimedia, LP, DKL, Delek, NYSE, Petroleum, Delek US

BRENTWOOD, Tenn., July 6, 2022 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the Company intends to issue a press release summarizing second quarter 2022 results before the U.S. stock market opens on Thursday, August 4, 2022.

Key Points: 
  • BRENTWOOD, Tenn., July 6, 2022 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the Company intends to issue a press release summarizing second quarter 2022 results before the U.S. stock market opens on Thursday, August 4, 2022.
  • Investors may also wish to listen to Delek Logistics Partners, LP's (NYSE: DKL) ("Delek Logistics") second quarter 2022 earnings conference call on Thursday, August 4, 2022 at 9:00 a.m. CT (10:00 a.m.
  • Market trends and information disclosed by Delek Logistics may be relevant to the logistics segment reported by Delek US.
  • Delek US and its affiliates also own the general partner and an approximate 80 percent limited partner interest in Delek Logistics.

Delek US Announces Special Dividend of $0.20 per share

Retrieved on: 
Tuesday, June 21, 2022
Dorado, Time, DK, Multimedia, Share repurchase, NYSE, Delek, Partnership, Holding company, Petroleum

BRENTWOOD, Tenn., June 21, 2022 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the board of directors declared a special dividend of $0.20 per share.

Key Points: 
  • BRENTWOOD, Tenn., June 21, 2022 /PRNewswire/ -- Delek US Holdings, Inc. (NYSE: DK) ("Delek US") today announced that the board of directors declared a special dividend of $0.20 per share.
  • The dividend is payable on July 20, 2022 to shareholders of record on July 12, 2022.
  • This special dividend is indicative of a robust macro environment for refining and complements the $64 million share repurchase, at $18.30 per share, from the Icahn Group on March 7, 2022, which represented approximately 5% of the shares outstanding at that time.
  • Delek US and its affiliates also own the general partner and an approximate 80 percent limited partner interest in Delek Logistics.